N-Acetyl Semax
low riskAlso: NA Semax · Acetyl Semax · N-Acetyl-Met-Glu-His-Phe-Pro-Gly-Pro
N-Acetyl Semax is an acetylated analog of Semax, a synthetic heptapeptide derived from the ACTH(4-10) sequence developed in Russia in the 1980s. The N-terminal acetyl modification improves metabolic stability and is believed to enhance bioavailability compared to standard Semax. Like Semax, it acts primarily on BDNF signaling and dopaminergic/serotonergic pathways. N-Acetyl Semax is not separately studied in clinical trials; its evidence base is inferred from Semax research, where it is used in Russia as an approved nootropic and neuroprotective drug.
Reported Benefits
Cognitive enhancement
Semax demonstrates improvements in attention, working memory, and processing speed in Russian clinical trials. N-Acetyl Semax is assumed to be at least as effective due to improved stability, but is not independently studied.
Neuroprotection and stroke recovery
Semax is approved in Russia for ischemic stroke, optic nerve disease, and TIA. Animal studies show significant neuroprotective effects in ischemia models. Human trial design and reporting quality varies.
BDNF upregulation
Semax reliably increases BDNF levels in animal and limited human studies, making it mechanistically relevant to neuroplasticity and learning.
Anxiety reduction
Anxiolytic effects reported in some animal models and user reports; weaker evidence than Selank for this specific application.
Mechanism of Action
N-Acetyl Semax upregulates BDNF (brain-derived neurotrophic factor) and its receptor TrkB, promoting neuronal survival and synaptic plasticity. It modulates dopaminergic and serotonergic transmission via ACTH receptor-independent pathways. The peptide also influences the enkephalinase system and has demonstrated neuroprotective properties in ischemia models. The acetyl group protects the N-terminus from aminopeptidase degradation, extending half-life relative to unmodified Semax.
Key Clinical Studies
Miasoedov et al. (1999)
Open-label, multi-center · 200
Semax improved neurological outcomes in ischemic stroke patients when administered intranasally within 24 hours
Kost et al. (2001)
Randomized controlled trial · 60
Semax improved cognitive function and attention in patients with ischemic stroke sequelae
Overview
N-Acetyl Semax is a chemical variant of Semax, a heptapeptide developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. Semax has been used clinically in Russia and some CIS countries since the 1990s for cognitive enhancement, stroke recovery, and optic nerve disease. The N-acetyl modification was developed to address the relatively short half-life of unmodified Semax, which is susceptible to aminopeptidase cleavage at the N-terminus. The modification prolongs the peptide’s metabolic stability without altering its core pharmacology.
Evidence Summary
The clinical evidence for Semax — and by extension N-Acetyl Semax — comes primarily from Russian and Ukrainian clinical trials, which are often not published in peer-reviewed Western journals and have variable methodological quality. The most credible data supports neuroprotective effects in stroke, BDNF upregulation, and cognitive improvements in neurologically impaired populations. Evidence in healthy individuals for “nootropic” enhancement is largely anecdotal and community-sourced. N-Acetyl Semax specifically has not been studied in clinical trials and its superiority over standard Semax is theoretical, based on pharmacokinetic reasoning.
Regulatory Status
N-Acetyl Semax is not FDA-approved. Semax is approved as a prescription drug in Russia (Россия). In the US, N-Acetyl Semax exists in a gray area — not a scheduled substance, not an approved drug, not approved for compounding. It circulates as a research peptide. Administration to humans is off-label and experimental.
Most Common Use Cases
Intranasal administration is the primary delivery method, as the nasal mucosa provides efficient CNS access. Users target cognitive enhancement (focus, memory, learning), mood stabilization, and neurological recovery. It is frequently stacked with Selank or N-Acetyl Selank for combined nootropic and anxiolytic effects.
✦ Sponsored
Stop Guessing About Your Health. Start Optimizing It.
Advanced diagnostics and licensed medical providers delivering personalized longevity care to uncover root causes, optimize health, and track progress virtually or in person.
Learn More →
Regulatory Status
Research OnlySafety Profile
Side Effects
- •Mild nasal irritation (intranasal route)
- •Headache (uncommon)
- •Transient increase in irritability or anxiety (rare, paradoxical)
- •Insomnia if dosed late in day
Contraindications
- •Active psychiatric conditions (use with caution — BDNF modulation may have complex effects)
- •Pregnancy
- •Known hypersensitivity to ACTH or melanocortin-related compounds
Drug Interactions
- •SSRI/SNRI antidepressants (additive serotonergic effects — monitor)
- •Stimulants (additive dopaminergic stimulation)
Primary Uses
Related Peptides
Planning a protocol?
Use the AI Stack Builder to generate a phased schedule, compatibility analysis, and monitoring checklist.
Weekly Briefing
Regulatory updates + new study breakdowns.
For Practitioners
Do you prescribe N-Acetyl Semax?
Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.
Get Listed →